Ripple Therapeutics Corporation, a clinical stage, ophthalmology-focused developer of novel pharmaceuticals, announced that the article Polymer-Free Corticosteroid Dimer Implants for Controlled and Sustained Drug Delivery was recently published in Nature Communications. The article describes Ripple's Epidel™ technology platform which is founded on a discovery that drugs can be engineered into drug delivery implants without the use of polymers or excipients.
Ripple Therapeutics Research on Polymer-Free Drug Delivery Published in Nature Communications
Previous
Previous
Toronto biotech startup Adela raises $60-million from top U.S. investors
Next
Next